Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sonnet Biotherapeutics Holdings Inc (SONN)

Sonnet Biotherapeutics Holdings Inc (SONN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,901
  • Shares Outstanding, K 7,078
  • Annual Sales, $ 20 K
  • Annual Income, $ -7,440 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.40
  • Price/Sales 16.03
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.12 +89.74%
on 11/04/25
5.95 -0.50%
on 11/14/25
+1.61 (+37.35%)
since 10/14/25
3-Month
2.71 +118.45%
on 09/05/25
7.90 -25.06%
on 09/16/25
+2.16 (+57.45%)
since 08/14/25
52-Week
1.08 +448.15%
on 05/27/25
19.30 -69.33%
on 07/14/25
+2.92 (+97.33%)
since 11/14/24

Most Recent Stories

More News
Sonnet to Present at the MedInvest Biotech & Pharma Conference

PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted...

SONN : 5.92 (+9.63%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HBI, BFIN, PBBK, SONN on Behalf of Shareholders

NEW YORK , Sept. 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

BFIN : 11.38 (-0.44%)
SONN : 5.92 (+9.63%)
PBBK : 20.48 (+2.09%)
HBI : 6.65 (+0.91%)
Sonnet Releases Virtual Investor "What This Means" Segment

- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) -  Watch...

SONN : 5.92 (+9.63%)
This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

Sonnet Bio is pivoting towards becoming a crypto treasury company by accumulating the HYPE Crypto.

MSTR : 199.75 (-4.22%)
^ETHUSD : 3,204.848 (+1.21%)
TSLA : 404.35 (+0.59%)
XYZ : 60.48 (-2.92%)
^BTCUSD : 95,845.98 (+0.83%)
SONN : 5.92 (+9.63%)
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ® ) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) ...

SONN : 5.92 (+9.63%)
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: SONN, SKX, FCCO, and SGBG

NEW YORK , July 18, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered...

SKX : 63.13 (-0.11%)
FCCO : 27.72 (-0.11%)
SONN : 5.92 (+9.63%)
SGBG : 17.0000 (-2.02%)
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

PRINCETON, N.J.

SONN : 5.92 (+9.63%)
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

SONN : 5.92 (+9.63%)
Sonnet Releases Virtual Investor "What This Means" Segment

SONN : 5.92 (+9.63%)
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

SONN : 5.92 (+9.63%)

Business Summary

Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J.

See More

Key Turning Points

3rd Resistance Point 8.46
2nd Resistance Point 7.21
1st Resistance Point 6.56
Last Price 5.92
1st Support Level 4.66
2nd Support Level 3.41
3rd Support Level 2.76

See More

52-Week High 19.30
Fibonacci 61.8% 12.34
Fibonacci 50% 10.19
Fibonacci 38.2% 8.04
Last Price 5.92
52-Week Low 1.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar